Patents by Inventor Andreas Vaupel

Andreas Vaupel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230307882
    Abstract: A laser head for a high power fiber laser system has a 5 to 10 mm high housing which is provided with a bottom. The housing encloses an input collimator assembly which collimates a single mode pump light at a fundamental frequency and maximum power of 2 kW. The housing further encases a multi-cascaded nonlinear frequency converter receiving the collimated pump light so as to convert the fundamental frequency into a higher harmonic thereof, wherein converted light at the higher frequency has a maximum power of 1 kW. Enclosed in the housing are electronic and light guiding optical components mounted in the housing. The bottom of the housing is an electro-optical printed circuit board (EO PCB) which directly supports the input collimator assembly, multi-cascaded nonlinear frequency converter, electronic and optical components at respective designated locations.
    Type: Application
    Filed: August 23, 2021
    Publication date: September 28, 2023
    Applicant: IPG PHOTONICS CORPORATION
    Inventors: Alexey AVDOKHIN, Andreas VAUPEL, Tetsuo OHARA, Kriti CHARAN, Jhih-An YANG
  • Patent number: 11702409
    Abstract: The present invention provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: July 18, 2023
    Assignee: NOVARTIS AG
    Inventors: Simona Cotesta, Marc Gerspacher, Catherine Leblanc, Edwige Liliane Jeanne Lorthiois, Bo Liu, Rainer Machauer, Robert Mah, Christophe Mura, Pascal Rigollier, Nadine Schneider, Stefan Stutz, Andrea Vaupel, Nicolas Warin, Rainer Wilcken
  • Publication number: 20220401422
    Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt form thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of disease.
    Type: Application
    Filed: April 27, 2021
    Publication date: December 22, 2022
    Inventors: Robin Alec FAIRHURST, Christine FRITSCH, Marc GERSPACHER, Jürgen Hans-Hermann HINRICHS, Jean-Baptiste Georges Armand LANGLOIS, Catherine LEBLANC, Tengfei LI, Edwige Liliane Jeanne LORTHIOIS, Christophe MURA, Cristina Montserrat NIETO-OBERHUBER, Milen TODOROV, Andrea VAUPEL, Nicolas WARIN, Rainer WILCKEN
  • Publication number: 20220363670
    Abstract: The present invention provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Application
    Filed: December 17, 2020
    Publication date: November 17, 2022
    Inventors: Simona Cotesta, Marc Gerspacher, Catherine Leblanc, Edwige Liliane Jeanne Lorthiois, Bo Liu, Rainer Machauer, Robert Mah, Christophe Mura, Pascal Rigollier, Nadine Schneider, Stefan Stutz, Andrea Vaupel, Nicolas Warin, Rainer Wilcken
  • Publication number: 20220149579
    Abstract: A laser system and method. In one example, the laser system includes an optical pulse stretcher configured to stretch pulse durations of an input train of input pulses to produce a train of stretched laser pulses, a pulse replicator module configured to increase a pulse repetition rate of the train of stretched laser pulses to produce a modified pulse train of laser light, a fiber power amplifier configured to amplify the modified pulse train to produce amplified laser pulses, and a pulse compressor that temporally compresses the amplified laser pulses to produce amplified and compressed laser pulses. The system may further include a nonlinear frequency conversion stage comprising at least one nonlinear crystal.
    Type: Application
    Filed: January 31, 2020
    Publication date: May 12, 2022
    Applicant: IPG PHOTONICS CORPORATION
    Inventors: Alex YUSIM, Igor SAMARTSEV, Manuel J. LEONARDO, Vadim SMIRNOV, Pankaj KADWANI, Alexey AVDOKHIN, Andreas VAUPEL
  • Patent number: 9890166
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: May 26, 2014
    Date of Patent: February 13, 2018
    Assignee: NOVARTIS AG
    Inventors: Jutta Blank, Guido Bold, Simona Cotesta, Vito Guagnano, Heinrich Rueeger, Andrea Vaupel
  • Patent number: 9556180
    Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: January 31, 2017
    Assignee: Novartis AG
    Inventors: Pascal Furet, Vito Guagnano, Philipp Holzer, Joerg Kallen, Robert Mah, Keiichi Masuya, Achim Schlapbach, Andrea Vaupel
  • Patent number: 9550796
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: January 24, 2017
    Assignee: NOVARTIS AG
    Inventors: Heinrich Rueger, Jutta Blank, Vincent Bordas, Simona Cotesta, Guido Bold, Vito Guagnano, Andrea Vaupel
  • Publication number: 20160280719
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: November 20, 2014
    Publication date: September 29, 2016
    Applicant: NOVARTIS AG
    Inventors: Jutta BLANK, Guido BOLD, Vincent BORDAS, Simona COTESTA, Vito GUAGNANO, Heinrich RUEGER, Andrea VAUPEL
  • Patent number: 9403827
    Abstract: The invention relates to compounds of formula (I): (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of as MDM2 and/or MDM4, and combinations comprising such compounds.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: August 2, 2016
    Assignee: NOVARTIS AG
    Inventors: Pascal Furet, Vito Guagnano, Philipp Holzer, Joerg Kallen, Robert Mah, Keiichi Masuya, Achim Schlapbach, Andrea Vaupel
  • Patent number: 9365576
    Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: June 14, 2016
    Assignee: Novartis AG
    Inventors: Simona Cotesta, Pascal Furet, Vito Guagnano, Philipp Holzer, Joerg Kallen, Robert Mah, Keiichi Masuya, Achim Schlapbach, Stefan Stutz, Andrea Vaupel
  • Publication number: 20160108047
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: May 26, 2014
    Publication date: April 21, 2016
    Applicant: NOVARTIS AG
    Inventors: Jutta BLANK, Guido BOLD, Simona COTESTA, Vito GUAGNANO, Heinrich RUEEGER, Andrea VAUPEL
  • Publication number: 20160095843
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: May 26, 2014
    Publication date: April 7, 2016
    Applicant: NOVARTIS AG
    Inventors: Jutta BLANK, Vincent BORDAS, Simona COTESTA, Vito NANO, Heinrich RUEEGER, Andrea VAUPEL
  • Publication number: 20150353563
    Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.
    Type: Application
    Filed: January 21, 2014
    Publication date: December 10, 2015
    Inventors: Pascal FURET, Vito GUAGNANO, Philipp HOLZER, Joerg KALLEN, Robert MAH, Keiichi MASUYA, Achim SCHLAPBACH, Andrea VAUPEL
  • Publication number: 20150353551
    Abstract: The invention relates to compounds of formula (I): (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of as MDM2 and/or MDM4, and combinations comprising such compounds.
    Type: Application
    Filed: January 21, 2014
    Publication date: December 10, 2015
    Applicant: NOVARTIS AG
    Inventors: Pascal FURET, Vito GUAGNANO, Philipp HOLZER, Joerg KALLEN, Robert MAH, Keiichi MASUYA, Achim SCHLAPBACH, Andrea VAUPEL
  • Patent number: 8975417
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: March 10, 2015
    Assignee: Novartis AG
    Inventors: Vincent Bordas, Simona Cotesta, Vito Guagnano, Heinrich Rueeger, Andrea Vaupel
  • Patent number: 8969341
    Abstract: The invention relates to compounds of formula (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: March 3, 2015
    Assignee: Novartis AG
    Inventors: Pascal Furet, Vito Guagnano, Philipp Holzer, Robert Mah, Keiichi Masuya, Achim Schlapbach, Stefan Stutz, Andrea Vaupel
  • Publication number: 20140350010
    Abstract: The invention relates to compounds of formula (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.
    Type: Application
    Filed: November 28, 2012
    Publication date: November 27, 2014
    Applicant: NOVARTIS AG
    Inventors: Pascal Furet, Vito Guagnano, Philipp Holzer, Robert Mah, Keiichi Masuya, Achim Schlapbach, Stefan Stutz, Andrea Vaupel
  • Publication number: 20140349990
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: May 20, 2014
    Publication date: November 27, 2014
    Applicant: NOVARTIS AG
    Inventors: Jutta BLANK, Vincent BORDAS, Simona COTESTA, Vito GUAGNANO, Heinrich RUEEGER, Andrea VAUPEL
  • Publication number: 20140343084
    Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.
    Type: Application
    Filed: July 10, 2014
    Publication date: November 20, 2014
    Inventors: Pascal FURET, Vito GUAGNANO, Philipp HOLZER, Joerg KALLEN, Lv LIAO, Robert MAH, Liang MAO, Keiichi MASUYA, Achim SCHLAPBACH, Stefan STUTZ, Andrea VAUPEL